ABSTRACT
1
There are many ways to calculate delta values, using either absolute or proportional changes. Also, many researchers have suggested their own ideas to calculate and set delta check limits. [1] [2] [3] [4] Recently published Clinical and Laboratory Standards Institute guidelines have suggested that reference change values (RCVs) can be used for set delta check limits. 5 Since the introduction of biological variation (BV) in clinical laboratories, its application has been expanded from judging the appropriate reference interval to setting analytical quality goals. [6] [7] [8] An RCV is one of the most highlighted uses of BV. It is claimed that it can be used to monitor serial changes in patients and set delta check limits and for autoverification. 5, 9, 10 On the other hand, there has been significant criticism regarding the use of BV in clinical laboratories. The concerns primarily pertain to the reliability of databases, data from healthy individuals being applied to critically ill patients, and assumptions of normality. [11] [12] [13] In the present study, we assessed the utility of RCVs as delta check limits in clinical laboratories using real-world data.
Materials and Methods
This study was approved by the institutional review board of Dongtan Sacred Heart Hospital (2017-001).
albumin (ALB), alkaline phosphatase (ALP), aspartate aminotransferase (AST), amylase (AMYL), alanine aminotransferase (ALT), urea nitrogen (BUN), calcium, cholesterol, chloride (CL), creatinine (CREA), direct bilirubin (DBIL), γ-glutamyl transferase (GGT), glucose (GLUC), high-density lipoprotein (HDL), potassium (K), low-density lipoprotein (LDL), lactate dehydrogenase (LDH), sodium (Na), total protein (PROT), inorganic phosphate (P), total bilirubin (TBIL), triglyceride, and uric acid (UA). All tests were performed using modular analyzers (Roche c702 [Roche Diagnostics, Mannheim, Germany]; Toshiba 2000FR [Toshiba Medical Systems, Otawara-shi, Japan]). Because all analytes were tested using two different instruments, comparability was evaluated biannually using fresh patient samples.
RCV Estimation
The RCVs for each analyte were estimated using the following formula 14 :
Z is 1.96 for two-sided approach (P < .05), coefficient of variation (CV A ) is analytical imprecision, and CV I is within-subject BV. CV A was calculated from the mean CV between August and December 2016, which was considered a representative interval of long-term imprecision.
Patient Data Analysis
Patients (aged ≥18 years) were categorized into four groups: outpatients (group 1), inpatients (group 2), emergency care (group 3), and general health screen (group 4). Patients were required to have two sets of records in the same category (tested) within 60 days, and only then were they selected for further evaluation. The 60-day restriction was not applied to patients in group 4 because their results were usually obtained 1 year apart.
For the paired results in the same patient, the percent differences (delta%) between the previous result (P) and current result (C) were computed using the following equation: delta% = C P / P *100 -( ) Distributions were assessed for each analyte. Specified percentile values (2.5th and 97.5th) were calculated from each delta% value for each analyte to compare with their RCV. The distributions were assessed for normality using the Kolmogorov-Smirnov test; P < .05 was considered statistically significant.
Statistical Analysis
All statistical analyses were performed using R version 3.3.0 (the R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org).
Results

Study Populations and Estimated RCV
During the study period, a total of 1,650,518 paired test results met the inclusion criteria. The minimum number of pairs was included for LDL in group 3 (26 pairs) and the maximum number for CL in group 2 (112,533 pairs), with a median of 2,611 pairs in each group. No pairs met the inclusion criteria in group 3 for GLUC and HDL.
RCVs for the test items are listed in ❚Table 1❚; they were highly variable, from 3.2% for Na to 102.1% for DBIL. The variability was mainly due to CV I (0.6%-36.8%), while CV A showed less variation (0.75%-2.90%).
Percentile Limits of Delta%
❚Table 2❚ and ❚Figure 1❚ show the estimated percentile limits of delta% values. Most of the estimated limits were larger than the corresponding RCVs, which means that the fluctuations in real-world patients were more than expected from the BV database and analytical 
Discussion
In the present study, we compared estimated RCVs with real-world patient data. For most of the analytes and patient groups, estimated RCVs were less than the estimated percentile limits. Furthermore, there were remarkable variations in the percentile limits across the patient groups.
Since the announcement from the Milan Consensus Statement, the importance of BV has been emphasized. There have been many studies aiming to collect additional BV data and expand their use. RCV has also been underscored, in part, because reference intervals from the general population have less utility for analytes with high individuality. 14 In contrast, some reports question the use of BV in clinical laboratories. First, determining the reliability of the source database is essential for BV application. Only a few studies have revealed the BV of many analytes, and even among these, some received criticism regarding the quality of their design. 12 Second, the applications of RCV were confidently based on the assumption that the test results followed a normal distribution. This issue has been thoroughly addressed in the previous literature, and some researchers have attempted to use logarithmic transformation or nonparametric approaches. 11, 15 Importantly, virtually all BV data were acquired from healthy populations or patients with stable chronic diseases. It is exceedingly difficult to construct an appropriate rationale for applying such data to acutely and/or critically ill patients.
In that sense, we evaluated the utility of integrating BV into clinical laboratories using RCV. As a result, ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMYL, amylase; AST, aspartate aminotransferase; BUN, urea nitrogen; CA, calcium; CHOL, cholesterol; CL, chloride; CREA, creatinine; DBIL, direct bilirubin; GGT, γ-glutamyl transferase; GLUC, glucose; HDL, high-density lipoprotein; K, potassium; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; Na, sodium; PROT, total protein; P, inorganic phosphate; RCV, reference change value; TBIL, total bilirubin; TG, triglyceride; UA, uric acid; -, not applicable. a Low, 2.5th percentile value for the delta% value in each group. High, 97.5th percentile value for the delta% value in each group. See text for details.
significant differences across the patient groups have been exposed. The delta% values were markedly more variable among ill patients than in individuals visiting for general health screens. This is not surprising because the various treatments-and the disease course itself-undoubtedly affect test results. In the present study, all of the delta% values in patients did not pass normality tests. This means that the test results in patients did not follow a Gaussian distribution and/or the intraindividual variations were not the same across the many patients. Regardless of the reason, the application of RCV was verified to be impractical because it requires that two fundamental assumptions are met: normal distribution and intraindividual variation comparability.
Analytes reflecting tissue damage, such as AST, ALT, GGT, LDH, AMYL, and ALP, and/or levels of analytes profoundly rising in response to patient conditions, such as BUN, CREA, DBIL, TBIL, UA, and P, demonstrated larger positive delta% (97.5th percentile) than negative ❚Figure 1❚ Estimated reference change values (RCVs) and specified percentile values (2.5th and 9.75th) for assessed analytes. Group 1, data from outpatients; group 2, data from inpatients; group 3, data from patients in the emergency care unit; group 4, data from individuals who underwent general health screen. See Table 1 for abbreviations. delta% (2.5th percentile). An example of GGT is displayed in ❚Figure 2❚, showing lagged tails on the rightward. This resulted from characteristics of the analytes themselves and may represent another factor that detracts from the application of RCV, which should set both limits equally.
Some analytes, such as ALB, PROT, Na, K, and CL, demonstrated relatively similar delta% values across the different patient groups. This was probably due to small variations in most of the patients. ❚Figure 3❚ shows an example of CL data. There was little variation across patient groups. Previous studies using electrolyte data have reported similar results. 10 Some aspects that limit the utility of RCV also affect the currently used delta check process itself. All of the distributions, especially in emergency care unit, showed skewed distributions (C). See Table 1 for abbreviations.
improve the process by modifying the application of limits, such as logarithmic transformation and/or grouping of patients. However, it would be challenging to build such systems in current laboratory information systems. Improvement of the delta check process should be of great interest and importance and will be the subject of subsequent studies.
In conclusion, we revealed some of the pitfalls of applying RCVs as delta check limits in clinical laboratories.
The same concerns may be valid for other applications of BV. Laboratory managers should be aware of the limitations of BV-derived values and exercise caution when using them. Figure 2 , the distributions showed relatively symmetric shapes. See Table 1 for abbreviations.
